Monsanto’s Water Utilization Learning Center is the first of its kind in agriculture. The $6 million facility was developed by Monsanto to share industry-leading knowledge and research, particularly in the area of water management. The Water Utilization Learning Center allows farmers and other stakeholders the opportunity to learn about water-use efficiency technologies in agriculture in … Read Full Press Release
DS Laboratories, Divine Skin’s first brand, begins Brazilian marketing operations with several level-1 cosmetics, including its Nia radiant-color shampoo and conditioner and Nirena pH-balanced feminine cleanser. Oligo.DX eliminates the unsightly appearance of dimpled fat, revealing smoother, firmer thighs, buttocks, and hips. The secret of its success is delivering active ingredients deeper, into lower layers of … Read Full Press Release
The Southern California Biomedical Council (SoCalBio) has announced the lineup of speakers for its first conference on cloud computing, which will be held Thursday, February 24th at the Jonathan Club in downtown Los Angeles. The day-long conference will help small and mid-size companies take advantage of “cloud” resources and other advancements in information technology that … Read Full Press Release
ConjuChem, LLC, a biotechnology company dedicated to the discovery of novel therapeutics, announced today the relaunch of the company under new management, headed by healthcare visionary and business leader Patrick Soon-Shiong, M.D. ConjuChem’s product development will be led by a team that has a proven track record of successfully developing and commercializing Abraxane(R), itself a … Read Full Press Release
XOMA is a leader in the discovery and development of novel antibody therapeutics. The company’s proprietary product pipeline includes: Certain statements contained herein concerning timing of initiation of clinical trials, or interim or other results of early-stage clinical trials, or that otherwise relate to future periods are forward-looking statements within the meaning of Section 27A … Read Full Press Release
ALTERNATIVE ENERGY PARTNERS INCORPORATED (OTCBB: AEGY) “Up 100.00% in morning trading” Alternative Energy Partners, Inc., a development stage company, engages in the energy production and management business in the United States. The company focuses on providing commercial buildings with advanced solar thermal energy production systems allowing businesses to use alternative energy sources. It intends to … Read Full Press Release
XLH is a rare metabolic bone disorder caused by excessive loss of phosphate in the urine leading to severe hypophosphatemia and poor bone growth and mineralization.XLH patients have low serum phosphate levels due to high levels of FGF23, a hormone that represses the reabsorption of phosphate from the urine.KRN23 is intended to bind to and … Read Full Press Release
The goals of this contract are to file IND applications for intravenous and intramuscular BCX4430 for the treatment of Marburg virus disease, and to conduct Phase 1 human clinical trials. This project will be funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of … Read Full Press Release
This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by 320 tables & figures over 280 pages. – By Company (e.g., JANSSEN, MYLAN, ACTAVIS, GLAXOSMITHKLINE, BAYER, NOVARTIS, NOVEN, LAVIPHARM, PROSTRACKEN, NITTO DENTO) – By Geography (Global, USA) – By … Read Full Press Release
Mr. Cole has more than 17 years of experience advising large and mid-tier pharmaceutical and biotech companies and academic institutions in such areas as strategy development and implementation. His areas of expertise focus on R&D, in particular R&D strategy, performance improvement, operating model design, and innovation management. He also has extensive experience assisting business development … Read Full Press Release
Visterra, Inc., a clinical-stage biotechnology company, today announced the appointment of Bernadette Connaughton, Head, European Markets, Canada and Australia of Bristol-Myers Squibb, and Steven Holtzman, former Executive Vice President, Corporate Development of Biogen, to the company’s board of directors. Ms. Connaughton and Mr. Holtzman each bring more than 30 years of strategic, operational and management … Read Full Press Release
For the third quarter of 2016, the company reported a net loss of $3.6 million, or $(0.02) per share, compared to net income for the third quarter of 2015 of $27.2 million, or $0.17 per share. Net loss for the first nine months of 2016 was $21.1 million, or $(0.13) per share, compared to net … Read Full Press Release
“With a large gap remaining between large BioPharma’s actual and desired revenues, and historically high amounts of cash on hand, look for an uptick of larger acquisition targets,” says David Risinger, an analyst for Morgan Stanley who covers big pharma. “This is particularly true of the U.S. BioPharma industry, where the amount of cash on … Read Full Press Release
Dr. Howard Verrico, CEO, has participated in the Private Placement with the purchase of 1,000,000 Units and upon completion, owns 5,951,250 common shares. All securities issued under the placement are subject to statutory hold periods expiring on February 26, 2018. Proceeds of the placement will be used for general working capital. About Sirona Biochem Corp. … Read Full Press Release
On the basis of product and service, the reagents & assay kits segment accounted for the largest share of the global HTS market. The large share of this segment can be attributed to factors such as the large numbers of reagents and assay kits used in HTS techniques, rising prevalence of a number of diseases, … Read Full Press Release
The scope of this study involves the tools and reagents employed in the life sciences markets. The life sciences markets include both the biotechnology and pharmaceutical industries. The tools and reagents covered in this report are used to conduct research in the domains of genomics (DNA and RNA research), proteomics, cell biology research, epigenetics, metabolomics, … Read Full Press Release
LEIDEN, NETHERLANDS — (Marketwire) — 09/11/09 — Biotech companyPharming Group NV (“Pharming”) (NYSE Euronext: PHARM) today providedan update on its outstanding number of shares following transactionswith YA Global Master SPV LTD (“YA Global”). Under the Standby Equity Distribution Agreement with YA Global,Pharming issued a total of 1,852,230 ordinary shares for a cashconsideration of EUR 1.0 … Read Full Press Release
This collaboration is a milestone-based approach in which NCI will first confirm the anti-cancer activity of LB-100 in an animal model of glioblastoma multiforme, the most common brain tumor of adults, and conduct an initial exploratory toxicology study in an animal model. At milestone intervals, the SAC will re-evaluate project progress before considering assignment of … Read Full Press Release
“With her strong background in the diagnostics industry, Christine’s strategic vision and considerable business experience have helped companies successfully develop, launch and market products,” said Ms. Danenberg, CEO. “And with our current growth rate in the double digits, her addition to the senior management team will help Response Genetics expand its market and realize its … Read Full Press Release
“This latest clearance from the FDA of our third OTC drug containing our proprietary NexACT(R) drug delivery technology, illustrates the progress we have achieved in a relatively short period of time toward building out our OTC Consumer Healthcare Division, and puts us one step closer to being able to provide a full-line of OTC products … Read Full Press Release
As such, this $3 million investment reflects a long-term interest in the Company on the part of the investor, and will provide for the continued acceleration of the Company’s GBM brain cancer clinical trial while the arrangements for the $25 million follow-on facility are being implemented. “We are pleased to receive strong support and long-term … Read Full Press Release
With downward pricing pressure and the need to control facility costs, life sciences companies are making calculated and strategic decisions for their facilities investments. The historical dynamic of mature-market R&D discovery vs. offshoring lower-value operations is slowly evolving as emerging markets increasingly drive consumer demand. “We are seeing even greater bifurcation of location strategies in … Read Full Press Release
September 4, 2013 – Beaverton, Oregon — “What is interesting about <a href=”eslana.com/why-weight-loss-programs-often-do-not-work/” target=”_blank”>weight loss</a> is that everyone has a trick up their sleeves. Some claim you cannot possibly lose weight without exercising for at least 2 hours a day”, while others claim that the only way to lose weight is to limit diets to … Read Full Press Release
The ‘Global and Chinese Xylitol Industry Report 2013’ is a professional and in-depth study on the current state of the global xylitol industry with a focus on the Chinese situation. The report provides a basic overview of the industry including definitions, classifications, applications, industry chain structure and overview. Xylitol market analysis is provided for both … Read Full Press Release
Cosmederm Bioscience, a leading specialty pharmaceutical company focused on dermatology and pain management, has hired Steve Massah as the company’s new Chief Operating Officer. As COO, Massah will provide strategic and tactical leadership, and management of manufacturing, product development, quality and product shipment and logistics. His work will ensure compliance with all government regulations and … Read Full Press Release
Alnylam Pharmaceuticals, Antisense Therapeutics, Arrowhead Research Corporation, AuraSense Therapeutics, BioMarin Pharmaceuticals, Dicerna Pharmaceuticals, Gene Signal International SA, Idera Pharmaceuticals, InDex Pharmaceuticals AB, Isarna Therapeutics GmbH, Isis Pharmaceuticals, Miragen Therapeutics, Mirna Therapeutics, Moderna Therapeutics, Mologen AG, Oncogenex Pharmaceuticals, Quark Pharmaceuticals, Regulus Therapeutics, RXi Pharmaceuticals, Sarepta Therapeutics, Silence Therapeutics Plc, Sirnaomics, Sterna Biologicals GmbH, Sylentis SA and … Read Full Press Release
New York, New York (PRWEB) April 21, 2016 The Human Vaccines Project announced today that Dr. Wayne C. Koff, Ph.D. has joined the organization as its first President and Chief Executive Officer (CEO). Dr. Koff joins the Project from the International AIDS Vaccines Initiative (IAVI), where he served for over 17 years, most recently as … Read Full Press Release
SAN CARLOS, CA–(Marketwired – November 04, 2016) – “Lion continues building momentum in broadening the utility of our TIL technology in new indications through internal R&D as well as with our collaborators. We recently announced our collaboration with the Karolinska Institute which expands the utility of TIL into two new indications, glioblastoma and pancreatic cancer. … Read Full Press Release
Bioimaging -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2021 Bioimaging Industry Description Bioimaging report covers Applications and the various modalities of Bioimaging for the global market. The Applications of Bioimaging include Diagnostics and Research and Development. The report provides an in depth analysis of each of the applications and modalities … Read Full Press Release
Due to a loss of, or defect in the SMN1 gene, people with SMA do not produce enough survival motor neuron (SMN) protein, which is critical for the maintenance of motor neurons. The severity of SMA correlates with the amount of SMN protein. People with Type 1 SMA, the type that requires the most intensive … Read Full Press Release